---
pmid: '35217685'
title: AP-4-mediated axonal transport controls endocannabinoid production in neurons.
authors:
- Davies AK
- Alecu JE
- Ziegler M
- Vasilopoulou CG
- Merciai F
- Jumo H
- Afshar-Saber W
- Sahin M
- Ebrahimi-Fakhari D
- Borner GHH
journal: Nat Commun
year: '2022'
full_text_available: false
pmcid: PMC8881493
doi: 10.1038/s41467-022-28609-w
---

# AP-4-mediated axonal transport controls endocannabinoid production in neurons.
**Authors:** Davies AK, Alecu JE, Ziegler M, Vasilopoulou CG, Merciai F, Jumo H, Afshar-Saber W, Sahin M, Ebrahimi-Fakhari D, Borner GHH
**Journal:** Nat Commun (2022)
**DOI:** [10.1038/s41467-022-28609-w](https://doi.org/10.1038/s41467-022-28609-w)
**PMC:** [PMC8881493](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881493/)

## Abstract

1. Nat Commun. 2022 Feb 25;13(1):1058. doi: 10.1038/s41467-022-28609-w.

AP-4-mediated axonal transport controls endocannabinoid production in neurons.

Davies AK(1), Alecu JE(2), Ziegler M(2)(3), Vasilopoulou CG(4), Merciai F(4)(5), 
Jumo H(2), Afshar-Saber W(2), Sahin M(2)(6), Ebrahimi-Fakhari D(2), Borner 
GHH(7).

Author information:
(1)Department of Proteomics and Signal Transduction, Max Planck Institute of 
Biochemistry, Martinsried, 82152, Germany. davies@biochem.mpg.de.
(2)Department of Neurology, The F.M. Kirby Neurobiology Center, Boston 
Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
(3)Department of Functional Neuroanatomy, Institute of Anatomy and Cell Biology, 
Heidelberg University, INF 307, Heidelberg, 69120, Germany.
(4)Department of Proteomics and Signal Transduction, Max Planck Institute of 
Biochemistry, Martinsried, 82152, Germany.
(5)Department of Pharmacy and PhD Program in Drug Discovery and Development, 
University of Salerno, 84084, Fisciano, SA, Italy.
(6)Rosamund Stone Zander Translational Neuroscience Center, Boston Children's 
Hospital, Harvard Medical School, Boston, MA, 02115, USA.
(7)Department of Proteomics and Signal Transduction, Max Planck Institute of 
Biochemistry, Martinsried, 82152, Germany. borner@biochem.mpg.de.

The adaptor protein complex AP-4 mediates anterograde axonal transport and is 
essential for axon health. AP-4-deficient patients suffer from a severe 
neurodevelopmental and neurodegenerative disorder. Here we identify DAGLB 
(diacylglycerol lipase-beta), a key enzyme for generation of the endocannabinoid 
2-AG (2-arachidonoylglycerol), as a cargo of AP-4 vesicles. During normal 
development, DAGLB is targeted to the axon, where 2-AG signalling drives axonal 
growth. We show that DAGLB accumulates at the trans-Golgi network of 
AP-4-deficient cells, that axonal DAGLB levels are reduced in neurons from a 
patient with AP-4 deficiency, and that 2-AG levels are reduced in the brains of 
AP-4 knockout mice. Importantly, we demonstrate that neurite growth defects of 
AP-4-deficient neurons are rescued by inhibition of MGLL (monoacylglycerol 
lipase), the enzyme responsible for 2-AG hydrolysis. Our study supports a new 
model for AP-4 deficiency syndrome in which axon growth defects arise through 
spatial dysregulation of endocannabinoid signalling.

Â© 2022. The Author(s).

DOI: 10.1038/s41467-022-28609-w
PMCID: PMC8881493
PMID: 35217685 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no competing interests.
